🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Italy / NCT06621264
Recruiting Not applicable

Exercise Activity to Improve Mobility in Patients With CKD and PAD

NCT06621264 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2025-05-31

Condition(s) studied

Chronic Kidney Disease Stage 3 and 4Peripheral Artery Disease (PAD)

Investigational drug(s) / intervention(s)

EXERCISE TRAINING WITH OR WITHOUT MEDICATIONControl (Standard treatment)

EXERCISE TRAINING WITH OR WITHOUT MEDICATION: Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\'s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.

Control (Standard treatment): Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices

Study summary

People affected by chronic kidney disease and concomitant diagnosed peripheral artery disease at intermediate stages, without contraindications to exercise therapy will be invited to participate in the study.

Whose providing informed consent, will be randomly assigned to one of two groups:

1. Exercise program receiving two daily 10-minute interval walking sessions at a slow increasing speed.
2. Control group: receiving usual care including optimal medical therapy and nutritional advice.

Patients of both groups will be measured at baseline, after the end of the exercise program (6-month) and at follow up (12-month). Outcome measures will include walking ability by the 6-minute walking test (primary outcome) and lower limbs perfusion, body composition, quality of life, laboratory outcomes and long-term hospitalizations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * chronic kidney disease at KDOQI stages III or IV and concomitant Peripheral artery disease at stages I, II, III; * ability to walk independently; * cognitive function to give informed consent identified by a Mini Mental Status Examination score greater or equal to 20/30 * absence of clinical conditions contraindicating exercise therapy (e.g., unstable angina, severe heart failure at NYHA class IV, anemia with lower than 10.0 g/dl). Exclusion Criteria: * major amputations; * major surgery planned in the next 3 months; * known comorbid conditions that may limit survival to less than 2 years; * inability or unwillingness to comply with protocol requirements.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
University Hospital of Ferrara Ferrara Italy Recruiting
Ospedale Pederzoli Peschiera del Garda Peschiera del Garda Italy Recruiting
Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli Reggio Calabria Italy Recruiting

More University Hospital of Ferrara trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06621264 on ClinicalTrials.gov ↗ ← All trials in Italy